Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.82 |
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | FAAH | O00519 | 4/20 | 0.66 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.57 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855952 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL16369362 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL18251841 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL4886198 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL23796509 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL24591641 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL24682133 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL23729790 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL20536079 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 | |
| SCHEMBL17466174 | 1.00 | SLC6A5 (0.82) | SLC6A5CASP2FAAHNAAADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | SLC6A5 3289/4885CASP2 2294/4885FAAH 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.